

# Stephen V Frye

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3551945/publications.pdf>

Version: 2024-02-01

137  
papers

11,864  
citations

36203

51  
h-index

28224

105  
g-index

146  
all docs

146  
docs citations

146  
times ranked

17252  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of $\alpha$ -Ketoglutarate-Dependent Dioxygenases. <i>Cancer Cell</i> , 2011, 19, 17-30.	7.7	2,340
2	The promise and peril of chemical probes. <i>Nature Chemical Biology</i> , 2015, 11, 536-541.	3.9	698
3	Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer. <i>Cell</i> , 2012, 149, 307-321.	13.5	637
4	A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. <i>Nature Chemical Biology</i> , 2011, 7, 566-574.	3.9	465
5	An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1. <i>ACS Chemical Biology</i> , 2013, 8, 1324-1334.	1.6	399
6	The art of the chemical probe. <i>Nature Chemical Biology</i> , 2010, 6, 159-161.	3.9	357
7	Too many roads not taken. <i>Nature</i> , 2011, 470, 163-165.	13.7	341
8	Discovery of $\alpha$ -Arrestin $\beta$ -Biased Dopamine D <sub>2</sub> Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18488-18493.	3.3	312
9	Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): $\alpha$ Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4339-4358.	2.9	259
10	Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8931-8942.	2.9	220
11	Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7950-7953.	2.9	206
12	The discovery of potent cRaf1 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 223-226.	1.0	204
13	Structure and Inhibition of Microbiome $\alpha$ -Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. <i>Chemistry and Biology</i> , 2015, 22, 1238-1249.	6.2	203
14	Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. <i>Blood</i> , 2015, 125, 346-357.	0.6	188
15	Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5844-5857.	2.9	177
16	Chelates as intermediates in nucleophilic additions to alkoxy ketones according to Cram's rule (cyclic) $\alpha$ ETQq0 0 0 rgBT /Overlock 10 T	6.6	161
17	Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors. <i>Science</i> , 2001, 291, 134-137.	6.0	160
18	Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. <i>Nature Chemical Biology</i> , 2013, 9, 184-191.	3.9	160

#	ARTICLE	IF	CITATIONS
19	A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. <i>Nature Chemical Biology</i> , 2016, 12, 180-187.	3.9	133
20	Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6139-6150.	2.9	127
21	UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7031-7041.	2.9	125
22	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 2257-2267.	3.9	124
23	Structure-Function Relationship Studies of $\beta$ -Arrestin-Biased Dopamine D <sub>2</sub> Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7141-7153.	2.9	118
24	Small-Molecule Ligands of Methyl-Lysine Binding Proteins. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2504-2511.	2.9	115
25	AMP Is an Adenosine A1 Receptor Agonist. <i>Journal of Biological Chemistry</i> , 2012, 287, 5301-5309.	1.6	113
26	US academic drug discovery. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 409-410.	21.5	96
27	Are chelates truly intermediates in Cram's chelate rule?. <i>Journal of the American Chemical Society</i> , 1990, 112, 6130-6131.	6.6	89
28	Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. <i>Chemistry and Biology</i> , 1999, 6, R3-R7.	6.2	89
29	Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen <sup>®</sup> -Based Assay for Antagonists of Methyl-Lysine Binding Proteins. <i>Journal of Biomolecular Screening</i> , 2010, 15, 62-71.	2.6	88
30	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 1672-1686.	1.6	85
31	Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6822-6833.	2.9	81
32	Donated chemical probes for open science. <i>ELife</i> , 2018, 7, .	2.8	80
33	Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 129-134.	1.3	67
34	6-Azasteroids: Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2352-2360.	2.9	66
35	Small-Molecule Ligands of Methyl-Lysine Binding Proteins: Optimization of Selectivity for L3MBTL3. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7358-7371.	2.9	66
36	Rapid-injection nuclear magnetic resonance investigation of the reactivity of .alpha.- and .beta.-alkoxy ketones with dimethylmagnesium: kinetic evidence for chelation. <i>Journal of the American Chemical Society</i> , 1987, 109, 1862-1863.	6.6	65

#	ARTICLE	IF	CITATIONS
37	Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2110-2124.	2.9	64
38	The Lipid Kinase PIP5K1C Regulates Pain Signaling and Sensitization. <i>Neuron</i> , 2014, 82, 836-847.	3.8	64
39	Tackling reproducibility in academic preclinical drug discovery. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 733-734.	21.5	62
40	MerTK as a therapeutic target in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 92-102.	0.6	62
41	Discovery and Clinical Development of Dutasteride, a Potent Dual 5 $\alpha$ -Reductase Inhibitor. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 405-421.	1.0	60
42	Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia. <i>PLoS ONE</i> , 2013, 8, e66755.	1.1	60
43	Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay. <i>ACS Chemical Biology</i> , 2020, 15, 290-295.	1.6	60
44	Tumor Endothelial Cells with Distinct Patterns of TGF $\beta$ -Driven Endothelial-to-Mesenchymal Transition. <i>Cancer Research</i> , 2015, 75, 1244-1254.	0.4	59
45	UNC1062, a new and potent Mer inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2013, 65, 83-93.	2.6	58
46	UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. <i>Clinical Cancer Research</i> , 2017, 23, 1481-1492.	3.2	58
47	6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5.alpha.-reductase. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 4313-4315.	2.9	56
48	Bringing together the academic drug discovery community. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 811-812.	21.5	56
49	Identification of a Fragment-like Small Molecule Ligand for the Methyl-lysine Binding Protein, 53BP1. <i>ACS Chemical Biology</i> , 2015, 10, 1072-1081.	1.6	56
50	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. <i>JCI Insight</i> , 2016, 1, e85630.	2.3	55
51	Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase by 6-Azaandrost-4-en-3-ones: Optimization of the C17 Substituent. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 2621-2627.	2.9	54
52	Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9683-9692.	2.9	54
53	Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing. <i>Nature Communications</i> , 2019, 10, 1931.	5.8	54
54	Asymmetric synthesis based on 1,3-oxathianes. 4. Mechanism of asymmetric induction in the reactions of oxathianyl ketones. <i>Journal of the American Chemical Society</i> , 1988, 110, 484-489.	6.6	53

#	ARTICLE	IF	CITATIONS
55	UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2367-2377.	1.9	53
56	Asymmetric synthesis of (R)- and (S)-citramalate in high enantiomeric purity. <i>Tetrahedron Letters</i> , 1985, 26, 3907-3910.	0.7	52
57	Identification of Non-Peptide Malignant Brain Tumor (MBT) Repeat Antagonists by Virtual Screening of Commercially Available Compounds. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7625-7631.	2.9	52
58	MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. <i>JCI Insight</i> , 2018, 3, .	2.3	51
59	Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing. <i>ACS Chemical Biology</i> , 2016, 11, 2475-2483.	1.6	46
60	Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. <i>Science Signaling</i> , 2019, 12, .	1.6	46
61	Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2014-2022.	1.9	45
62	Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9693-9700.	2.9	43
63	Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2. <i>ACS Combinatorial Science</i> , 2017, 19, 161-172.	3.8	43
64	Assessing Protein Methyltransferase and Demethylase Enzymology Using Microfluidic Capillary Electrophoresis. <i>Chemistry and Biology</i> , 2010, 17, 695-704.	6.2	41
65	Target 2035 – update on the quest for a probe for every protein. <i>RSC Medicinal Chemistry</i> , 2022, 13, 13-21.	1.7	39
66	Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7. <i>Cell Chemical Biology</i> , 2019, 26, 1365-1379.e22.	2.5	38
67	Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1443-1454.	2.9	38
68	Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 6722-6736.	0.8	38
69	Prevention of chelation by an oxygen function through protection with a triisopropyl silyl group. <i>Tetrahedron Letters</i> , 1986, 27, 3223-3226.	0.7	37
70	Synthesis of 2-aminobenzophenones via rapid halogen-lithium exchange in the presence of a 2-amino-N-methoxy-N-methylbenzamide. <i>Journal of Organic Chemistry</i> , 1991, 56, 3750-3752.	1.7	37
71	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2297-2308.	1.9	36
72	Non-enzymatic asymmetric synthesis of (R)-(-)- and (S)-(+)-mevalolactone in high enantiomeric purity. <i>Journal of Organic Chemistry</i> , 1985, 50, 3402-3404.	1.7	35

#	ARTICLE	IF	CITATIONS
73	Biophysical Probes Reveal a "Compromise" Nature of the Methyl-lysine Binding Pocket in L3MBTL1. <i>Journal of the American Chemical Society</i> , 2011, 133, 5357-5362.	6.6	35
74	Structure-activity relationships of methyl-lysine reader antagonists. <i>MedChemComm</i> , 2012, 3, 45-51.	3.5	33
75	Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. <i>PLoS Pathogens</i> , 2018, 14, e1007267.	2.1	32
76	Target class drug discovery. <i>Nature Chemical Biology</i> , 2017, 13, 1053-1056.	3.9	31
77	Drug Discovery Toward Antagonists of Methyl-Lysine Binding Proteins. <i>Current Chemical Genomics</i> , 2011, 5, 51-61.	2.0	31
78	Writing and Rewriting the Epigenetic Code of Cancer Cells: From Engineered Proteins to Small Molecules. <i>Molecular Pharmacology</i> , 2013, 83, 563-576.	1.0	30
79	Targeting Chromatin Readers. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 312-314.	2.3	29
80	Epigenetics: tools and technologies. <i>Drug Discovery Today: Technologies</i> , 2010, 7, e59-e65.	4.0	28
81	Structure-Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8913-8923.	2.9	28
82	High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3018-3023.	3.3	26
83	Orally Active Adenosine A1 Receptor Agonists with Antinociceptive Effects in Mice. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6467-6477.	2.9	25
84	Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors. <i>ChemMedChem</i> , 2017, 12, 207-213.	1.6	25
85	MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members. <i>Clinical Cancer Research</i> , 2018, 24, 6523-6535.	3.2	25
86	A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins. <i>SLAS Discovery</i> , 2019, 24, 693-700.	1.4	25
87	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface. <i>MedChemComm</i> , 2013, 4, 1501.	3.5	24
88	Chemical probes for methyl lysine reader domains. <i>Current Opinion in Chemical Biology</i> , 2016, 33, 135-141.	2.8	24
89	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 278-288.	1.9	24
90	MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2016, 11, e0165107.	1.1	23

#	ARTICLE	IF	CITATIONS
91	Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10242-10254.	2.9	20
92	Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 1044-1049.	1.3	19
93	UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL. <i>Blood</i> , 2011, 118, 2589-2589.	0.6	17
94	Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. <i>Biochemistry</i> , 2018, 57, 2140-2149.	1.2	16
95	Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16541-16550.	3.3	16
96	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa065.	0.4	16
97	Use of Protein Kinase- <i>€</i> Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors. <i>SLAS Discovery</i> , 2018, 23, 982-988.	1.4	15
98	Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine. <i>Current Opinion in Chemical Biology</i> , 2021, 63, 132-144.	2.8	14
99	Inhibitors paradoxically prime kinases. <i>Nature Chemical Biology</i> , 2009, 5, 448-449.	3.9	12
100	Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. <i>Journal of the American Chemical Society</i> , 2019, 141, 15700-15709.	6.6	12
101	Discovery of selective activators of PRC2 mutant EED-I363M. <i>Scientific Reports</i> , 2019, 9, 6524.	1.6	12
102	Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins. <i>Molecules</i> , 2020, 25, 979.	1.7	12
103	Discovery and Optimization of 2- <i>H</i> -1 <sup>2</sup> -Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4913-4946.	2.9	12
104	Discovery of an H3K36me3-Derived Peptidomimetic Ligand with Enhanced Affinity for Plant Homeodomain Finger Protein 1 (PHF1). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8510-8522.	2.9	12
105	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. <i>Cell Chemical Biology</i> , 2022, 29, 555-571.e11.	2.5	12
106	MERTK activation drives osimertinib resistance in EGFR-mutant non- <i>€</i> small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
107	Discovery and Characterization of Peptide Inhibitors for Calcium and Integrin Binding Protein 1. <i>ACS Chemical Biology</i> , 2020, 15, 1505-1516.	1.6	11
108	The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells. <i>Epigenetics and Chromatin</i> , 2020, 13, 44.	1.8	10

#	ARTICLE	IF	CITATIONS
109	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitorsâ€”What Is Expected?. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6973-6974.	2.9	10
110	Targeting Methyl Lysine. <i>Annual Reports in Medicinal Chemistry</i> , 2010, 45, 329-343.	0.5	9
111	Design, synthesis, and protein methyltransferase activity of a unique set of constrained amine containing compounds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4436-4440.	1.0	8
112	The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer. <i>ACS Chemical Biology</i> , 2016, 11, 722-728.	1.6	8
113	Development of [ <sup>18</sup> F]MIPS15692, a radiotracer with inÂvitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113822.	2.6	5
114	Unlocking the potential of chemical probes for methyl-lysine reader proteins. <i>Future Medicinal Chemistry</i> , 2015, 7, 1831-1833.	1.1	4
115	Peptide Technologies in the Development of Chemical Tools for Chromatinâ€Associated Machinery. <i>Drug Development Research</i> , 2017, 78, 300-312.	1.4	4
116	UNC5293, a potent, orally available and highly MERTK-selective inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113534.	2.6	4
117	Bone Marrow Stromal Cell Mediated Resistance to MERTK Inhibition in Acute Leukemia. <i>Blood</i> , 2016, 128, 2819-2819.	0.6	4
118	MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Confering FLT3 Mutations in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3757-3757.	0.6	3
119	Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 1184-1184.	0.6	3
120	Discovery of Potent Peptidomimetic Antagonists for Heterochromatin Protein 1 Family Proteins. <i>ACS Omega</i> , 2022, 7, 716-732.	1.6	3
121	Drug discovery in academic institutions. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 300-305.	0.9	2
122	Mer Receptor Tyrosine Kinase. <i>Annual Reports in Medicinal Chemistry</i> , 2014, 49, 301-314.	0.5	2
123	A High-Throughput Screening-Compatible Strategy for the Identification of Inositol Pyrophosphate Kinase Inhibitors. <i>PLoS ONE</i> , 2016, 11, e0164378.	1.1	2
124	Novel Therapeutics Targeting Epigenetics: New Molecules, New Methods. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 123-123.	1.3	2
125	MerTK activity is not necessary for the proliferation of glioblastoma stem cells. <i>Biochemical Pharmacology</i> , 2021, 186, 114437.	2.0	2
126	Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1317-1317.	0.6	2



#	ARTICLE	IF	CITATIONS
127	Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Inhibit Platelet Aggregation In Vitro and Protect Mice From Arterial and Venous Thrombosis In Vivo. <i>Blood</i> , 2013, 122, 2296-2296.	0.6	1
128	MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4044-4044.	0.6	1
129	Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis. <i>Blood</i> , 2018, 132, 4019-4019.	0.6	1
130	Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo.. <i>Blood</i> , 2012, 120, 2607-2607.	0.6	0
131	A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, iMer, the Novel MerTK Splice Variant. <i>Blood</i> , 2012, 120, 3303-3303.	0.6	0
132	Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1957-1957.	0.6	0
133	Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Mediate Synergistic Inhibition Of Platelet Aggregation In Combination With ADP/P2Y Antagonists. <i>Blood</i> , 2013, 122, 3507-3507.	0.6	0
134	UNC1666, a Dual Mer and Flt-3 Tyrosine Kinase Small Molecule Inhibitor In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3849-3849.	0.6	0
135	Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2666-2666.	0.6	0
136	UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia. <i>Blood</i> , 2014, 124, 998-998.	0.6	0
137	Abstract 3339: MRX-2843, a dual MERTK and FLT3 inhibitor, mediates synergistic anti-leukemia activity in combination with BCL-2 inhibitors in acute myeloid leukemia and early T-cell precursor acute lymphoblastic leukemia. <i>Cancer Research</i> , 2022, 82, 3339-3339.	0.4	0